1
The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy.
2
Anti-TNF therapies appear to attenuate the injurious effects of TNF.
3
Anti-TNF therapy is associated with a significantly increased risk of developing hypertension in patients with RA.
4
Future studies are needed to evaluate pharmacogenetics as a predicting marker in anti-TNF therapy in sarcoidosis.
5
Methods: We performed a systematic literature review of studies investigating anti-TNF therapy, CD, and postoperative recurrence.
6
Similarly, anti-TNF therapy with infliximab is reported to be rapidly effective in inducing and maintaining remission.
7
Conclusions: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23.
8
Thus, for patients with RA, anti-TNF therapies set a new standard for symptom control and joint protection.
9
We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy.
10
The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy.
11
Anti-TNF therapy is associated with reduced risk of surgery and appears to alter the natural history of this complication.
12
Aims: To evaluate the effect of anti-TNF therapy on the HRQoL of patients with CPF in daily clinical practice.
13
This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.
14
Numbers needed to treat were calculated to compare the effect size of anti-TNF therapy between the AS matrix subpopulations.
15
The combination of both factors induced decreased anti-TNF-a levels and a higher percentage of patients on intensified anti-TNF therapy.
16
We aimed to determine the effect of preoperative anti-TNF therapy on postoperative complications in IBD patients undergoing abdominal surgery.
